Literature DB >> 34104529

Transcatheter tricuspid valve-in-valve implantation in a dysfunctional bioprosthetic valve.

Alper Güzeltaş1, İbrahim Cansaran Tanıdır1, Bekir Yükcü1, Erman Cilsal1, Murat Şahin1.   

Abstract

Entities:  

Year:  2021        PMID: 34104529      PMCID: PMC8167470          DOI: 10.5606/tgkdc.dergisi.2021.20728

Source DB:  PubMed          Journal:  Turk Gogus Kalp Damar Cerrahisi Derg        ISSN: 1301-5680            Impact factor:   0.332


× No keyword cloud information.

Introduction

A 23-year-old female patient was being followed due to Ebstein anomaly since birth. Cone procedure was performed, when the patient reached 21 years old, due to the increased tricuspid valve insufficiency and New York Heart Association (NYHA) Functional Class IV. Valve insufficiency was considered mild-to-moderate postoperatively. One month after the operation, the patient referred to the hospital with heart failure and echocardiography revealed severe tricuspid valve insufficiency. A Pericarbon More™ stented biological valve (Sorin Group, Saluggia, Italy) No. 31 was surgically implanted in the tricuspid position and an epicardial pacemaker was implanted due to permanent atrioventricular block after surgery. Although tricuspid valve functions were good during the early postoperative period, valve functions were gradually deteriorated over time. Two years after surgery, transthoracic and transesophageal echocardiography revealed that one of the Pericarbon More™ valve leaflets was immobile, while the other leaflets were thickened, resulting in severe tricuspid valve insufficiency and moderate tricuspid valve stenosis (Video 1 and 2). The patient was admitted to cardiac catheterization lab for transcatheter tricuspid valve-in-valve implantation. A 29-mm Edwards Sapien-XT® valve (Edwards Lifesciences Corp., CA, USA) was prepared with adding 2-cc extra volume to its balloon. The pacing rate of the epicardial pacemakers pacing rate increased to 180 bpm during valve implantation into the tricuspid position (Video 3). Severe tricuspid valve insufficiency and stenosis were diminished after new valve implantation. Angiographic stenosis gradient decreased from 15 mmHg to 5 mmHg, and the valve functions were good in the post-interventional period with no valvular insufficiency (Video 4 and 5). In conclusion, transcatheter valve implantation into the bioprosthesis at the tricuspid valve position is an effective method for reducing the number of repetitive surgical interventions.[1-3]
  3 in total

Review 1.  Transcatheter Tricuspid Valve-in-Valve and Valve-in-Ring Implantation for Degenerated Surgical Prosthesis.

Authors:  Saurabh Sanon; Allison K Cabalka; Vasilis Babaliaros; Charanjit Rihal; Sameer Gafoor; John Webb; Azeem Latib
Journal:  JACC Cardiovasc Interv       Date:  2019-07-17       Impact factor: 11.195

2.  Tricuspid transcatheter valve-in-valve: an alternative for high-risk patients.

Authors:  Diego Felipe Gaia; José Honório Palma; José Augusto Marcondes de Souza; Enio Buffolo
Journal:  Eur J Cardiothorac Surg       Date:  2012-03       Impact factor: 4.191

3.  Transcatheter Tricuspid Valve-in-Valve Implantation for the Treatment of Dysfunctional Surgical Bioprosthetic Valves: An International, Multicenter Registry Study.

Authors:  Doff B McElhinney; Allison K Cabalka; Jamil A Aboulhosn; Andreas Eicken; Younes Boudjemline; Stephan Schubert; Dominique Himbert; Jeremy D Asnes; Stefano Salizzoni; Martin L Bocks; John P Cheatham; Tarek S Momenah; Dennis W Kim; Dietmar Schranz; Jeffery Meadows; John D R Thomson; Bryan H Goldstein; Ivory Crittendon; Thomas E Fagan; John G Webb; Eric Horlick; Jeffrey W Delaney; Thomas K Jones; Shabana Shahanavaz; Carolina Moretti; Michael R Hainstock; Damien P Kenny; Felix Berger; Charanjit S Rihal; Danny Dvir
Journal:  Circulation       Date:  2016-03-18       Impact factor: 29.690

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.